Clinical trial · Interventional
A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion in Subjects With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX 01 003)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ADH -1 (Exherin™) | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Signed written informed consent * Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists * Clinically or radiologically documented measurable disease. * Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue * Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG) Exclusion criteria: * Receipt of ADH-1 prior to this clinical study * Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry * History of primary brain tumors or brain metastases * History of spinal cord compression or tumors that have shown any evidence of active bleeding within 30 days before study entry. * Stroke, major surgery, or other major tissue injury within 30 days before study entry * History of congestive heart failure, myocardial infarction, angina, life threatening arrhythmias, significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states
References
Publications (0)
Data not yet available